Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Consolidated Net Income: 2019-2023

Historic Consolidated Net Income for ADC Therapeutics (ADCT) over the last 5 years, with Sep 2023 value amounting to -$45.3 million.

  • ADC Therapeutics' Consolidated Net Income rose 12.93% to -$45.3 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$153.5 million, marking a year-over-year decrease of 11.71%. This contributed to the annual value of -$153,522 for FY2022, which is 43.76% up from last year.
  • As of Q3 2023, ADC Therapeutics' Consolidated Net Income stood at -$45.3 million, which was up 6.01% from -$48.2 million recorded in Q2 2023.
  • ADC Therapeutics' Consolidated Net Income's 5-year high stood at -$16,223 during Q4 2022, with a 5-year trough of -$126.3 million in Q2 2020.
  • For the 3-year period, ADC Therapeutics' Consolidated Net Income averaged around -$44.1 million, with its median value being -$51.3 million (2021).
  • Its Consolidated Net Income has fluctuated over the past 5 years, first tumbled by 480,314.45% in 2020, then surged by 79.29% in 2022.
  • Quarterly analysis of 5 years shows ADC Therapeutics' Consolidated Net Income stood at -$35,055 in 2019, then slumped by 65,908.76% to -$20.3 million in 2020, then plummeted by 250.44% to -$78,323 in 2021, then spiked by 79.29% to -$16,223 in 2022, then increased by 12.93% to -$45.3 million in 2023.
  • Its Consolidated Net Income was -$45.3 million in Q3 2023, compared to -$48.2 million in Q2 2023 and -$60.0 million in Q1 2023.